Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when the Republican state of Texas sued them. The complaint says that the companies didn’t tell people about the possible risks of taking acetaminophen while pregnant.

The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year.

Kenvue, the household staple behind Tylenol, has inked a deal to sell itself to Kimberly-Clark in a $48.7 billion deal. The tie-up will create a consumer goods giant which could generate a combined $32 billion in annual revenue.

Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.

Kenvue stock share price today shows a major surge after Kimberly-Clark announced plans to buy Kenvue for over $40 billion. The cash-and-stock deal will merge brands like Huggies, Kleenex, Tylenol, and Band-Aid under one company,

Texas Attorney General suing Tylenol over autism link; Who owns Tylenol? What to know about the makers of Tylenol and lawsuit claims.